Amgen Inc. $AMGN Stock Holdings Decreased by Wedbush Securities Inc.

Wedbush Securities Inc. lowered its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 4.2% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 29,667 shares of the medical research company’s stock after selling 1,314 shares during the quarter. Wedbush Securities Inc.’s holdings in Amgen were worth $12,505,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also modified their holdings of the company. Vision Financial Markets LLC acquired a new position in shares of Amgen during the third quarter worth $927,000. Fifth Third Wealth Advisors LLC lifted its holdings in shares of Amgen by 2.8% during the 3rd quarter. Fifth Third Wealth Advisors LLC now owns 9,517 shares of the medical research company’s stock valued at $4,012,000 after purchasing an additional 257 shares during the last quarter. Sterling Capital Management LLC boosted its position in shares of Amgen by 38.5% in the 3rd quarter. Sterling Capital Management LLC now owns 80,862 shares of the medical research company’s stock worth $34,084,000 after purchasing an additional 22,485 shares in the last quarter. James Investment Research Inc. boosted its position in shares of Amgen by 3.3% in the 3rd quarter. James Investment Research Inc. now owns 4,516 shares of the medical research company’s stock worth $1,904,000 after purchasing an additional 145 shares in the last quarter. Finally, TSA Wealth Managment LLC acquired a new stake in shares of Amgen in the 3rd quarter worth $228,000. 76.50% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

AMGN has been the subject of several recent analyst reports. TD Cowen raised their price target on Amgen from $420.00 to $452.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Wells Fargo & Company lowered their target price on shares of Amgen from $435.00 to $430.00 and set an “equal weight” rating for the company in a research note on Monday, October 12th. Barclays boosted their target price on shares of Amgen from $380.00 to $400.00 and gave the stock an “equal weight” rating in a research report on Wednesday. Morgan Stanley cut their price target on shares of Amgen from $362.00 to $359.00 and set an “equal weight” rating on the stock in a research note on Wednesday, October 7th. Finally, Truist Financial raised their price target on shares of Amgen from $362.00 to $380.00 and gave the stock a “hold” rating in a report on Wednesday, October 7th. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, sixteen have issued a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat, Amgen has a consensus rating of “Hold” and a consensus price target of $389.71.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Analyst remains bullish: Piper Sandler maintained its Buy rating and a $457 price target, implying continued confidence in Amgen’s earnings outlook, cash generation and pipeline. Piper Sandler Keeps Buy Rating on Amgen
• Positive Sentiment: Pipeline progress provides a potential catalyst: Amgen’s bemarituzumab study in gastric cancer has reached the Phase 3 finish line. While the report does not provide final efficacy or regulatory results, completion of the trial could eventually support a new oncology growth opportunity. Amgen Bemarituzumab Trial Update
• Neutral Sentiment: Tezspire update offers limited immediate clarity: Amgen reported results for Tezspire, but the available headline does not specify the clinical findings or their commercial implications. Investors will need additional detail to assess the impact on sales expectations. Amgen Reports Tezspire Results
• Negative Sentiment: Patent-cliff and dividend concerns are resurfacing: Coverage questions whether Amgen can protect its dividend when major products lose patent protection. The issue may weigh on the stock because investors are evaluating whether future cash flow can support both shareholder returns and replacement growth. Amgen Dividend and Patent Cliff Risks

Amgen Stock Performance

Shares of NASDAQ:AMGN traded down $8.02 during trading on Friday, hitting $439.26. 2,074,327 shares of the stock traded hands, compared to its average volume of 2,762,786. The company has a quick ratio of 1.13, a current ratio of 1.37 and a debt-to-equity ratio of 4.44. The company has a fifty day moving average price of $417.70 and a two-hundred day moving average price of $377.83. Amgen Inc. has a 52-week low of $288.00 and a 52-week high of $450.98. The company has a market cap of $237.48 billion, a price-to-earnings ratio of 27.30, a P/E/G ratio of 3.28 and a beta of 0.41.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.62 by $0.67. The firm had revenue of $10.05 billion for the quarter, compared to the consensus estimate of $9.43 billion. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The firm’s quarterly revenue was up 9.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $6.02 earnings per share. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, equities analysts predict that Amgen Inc. will post 22.94 EPS for the current year.

Amgen Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, September 11th. Shareholders of record on Friday, August 21st were given a $2.52 dividend. The ex-dividend date was Friday, August 21st. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.3%. Amgen’s dividend payout ratio is 62.65%.

Insider Transactions at Amgen

In other Amgen news, SVP Nancy Grygiel sold 2,970 shares of the company’s stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $402.16, for a total value of $1,194,415.20. Following the completion of the transaction, the senior vice president owned 7,340 shares in the company, valued at approximately $2,951,854.40. This represents a 28.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Rachna Khosla sold 2,000 shares of the stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $412.57, for a total transaction of $825,140.00. Following the sale, the senior vice president directly owned 6,404 shares in the company, valued at approximately $2,642,098.28. The trade was a 23.80% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 6,222 shares of company stock valued at $2,540,926. Insiders own 0.85% of the company’s stock.

About Amgen

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

The company’s products include biologic and specialty medicines such as Enbrel for inflammatory diseases, Prolia and Evenity for osteoporosis, Xgeva for skeletal-related complications, Repatha for cardiovascular risk reduction, Otezla for inflammatory conditions, Tezspire for severe asthma, Blincyto for certain blood cancers, and Lumakras for specific cancers.

Founded in 1980, Amgen is headquartered in Thousand Oaks, California.